Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Invitrogen, a provider of life science technologies for research, production and diagnostics, has signed non-exclusive agreements with New England Biolabs, Qiagen and Kirkegaard & Perry Laboratories, whereby the companies have licensed Invitrogen's patented technology covering the random prime amplification of nucleic acids. Financial terms of the agreements were not disclosed.
Subscribe to our email newsletter
The Invitrogen technology covered in these agreements involves methods and kits for substantially amplifying nucleic acids. It is reported to be useful in several common laboratory techniques, including random primed labeling reactions, first-strand cDNA synthesis and whole genome amplification.
Amy Butler, Invitrogen’s vice president of gene expression profiling, said: “By making this technology broadly available to other companies through licensing, we can extend the benefit to a greater number of researchers and advance this rapidly growing field of research. Our random prime amplification technology is an important tool in our premier portfolio of products for genetic analysis.”